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ABSTRACT 
A study was conducted to investigate the seroprevalence of the rubella virus amongst pregnant 
women and the relationship it has with the duration of pregnancy, premature delivery, and past 
history of abortion in pregnant women visiting the Yaoundé Gynecological, Obstetric and Pediatric 
Hospital (HGOPY). 211 pregnant women attending the prenatal consultation of mean age 27±5.99 
years were randomly selected and screened for rubella IgG antibodies.  39.3% of them were in their 
third trimester of pregnancy while 25.6% and 35.1% were in their first and second trimester of 
pregnancy respectively. 11.73% of the women had a history of premature delivery and 40.3% had a 
history of at least one abortion. Spearman's correlation was calculated between antibody titre and 
age. 88.6% of pregnant women were seropositive while 9% (susceptible) were seronagative and 2.4% 
had equivocal results. The most susceptible women to rubella infection were in the age group 26-30 
years while women in the age group 21-25 years band were the most seropositive. There was a 
strong correlation between the antibody titre and age (r=0.549 p<0.01). There was no statistical 
difference between the pregnancy in trimesters and antibody titres (p=0.0926) as well as between the 
number of previous abortions and the antibody titre (p<0.01, r=0.246). No correlations between 
antibody titre and pregnancy duration, or occurrence of premature births. There was a weak 
correlation between the antibody titre and number of previous abortions.  
 
INTRODUCTION 
Rubella virus is an infection caused by a 
virus of the genus Rubivirus of the Togavirus 
family [1]. It has a simple architectural 
structure of single stranded RNA genome 
enclosed by an icosahedral nucleocapsid, 
protected by a lipid bilayer membrane [2-4]. 
Rubella (which means “little red” and is also 
known as German measles) was originally 
thought to be a variant of measles. It is a 
mild disease in children and adults, but can 
cause devastating problems if it infects the 
fetus, especially when the infection occurs 
during the first weeks of pregnancy [1, 2]. 
This is known as congenital rubella 
syndrome (CRS). When a woman is infected 
with the rubella virus early in pregnancy she 
has a 90% chance of passing the virus unto  
 
the fetus [2, 3]. This can cause the death of 
the fetus, it may cause CRS. The 
complications include hearing loss, 
congenital heart defects, neurologic 
problems (psychomotor retardation), 
ophthalmic problems (cataract, glaucoma, 
and retinopathy) intrauterine growth 
retardation, hepatomegaly, splenomegaly [2, 
3, 4]. There may also be variety of other 
problems including bone lesions [1, 3]. Virus 
from congenital infections persists after birth 
and persons with congenital infections has 
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the potential to infect others after birth for a 
year or more [2, 5].The virus occurs in naso-
pharyngeal secretions, urine and feces. 
Later on, patients with congenital syndrome 
may develop additional complications 
including diabetes mellitus (up to 20%), 
thyroid dysfunction, growth hormone 
deficiency; ocular complications [2, 3, 
6].When a woman is infected with the 
rubella virus, the body produces both 
immunoglobin G (IgG) and immunoglobulin 
M (IgM) antibodies to fight against infection 
[2, 4, 7]. Once IgG exists, it persists for a 
lifetime, but IgM antibody usually wanes 
over six months [3]. 
 If rubella IgG is present it can be confirmed 
that a patient has immunity to rubella. 
Specific IgG determination is performed 
through enzyme Linked Immunosorbent 
Assay (ELISA) techniques. The results are 
expressed in IU/ml. [1, 4, 8]. The microbial 
world is complex and constantly evolving 
and despite scientific efforts to contain 
diseases with microbial etiology, the growth 
of international travel has increased the 
ease with which microbes formerly restricted 
to certain geographical areas are spread 
across continents [5] For instance the recent 
movement of people fleeing the war in Chad 
to Cameroon is a situation that could trigger 
the spread of the rubella virus amongst 
unvaccinated population. Rubella is one of 
the most common causes of birth defects in
 
the world, resulting in spontaneous 
abortions, stillbirths,
 
and congenital rubella 
syndrome (CRS) rubella rashes [2, 3, 8, 9]. 
The manifestations of
 
CRS include hearing 
impairment, blindness, heart defects, and
 
mental retardation. According to the World 
Health Organization,
 
in 1996, two thirds of 
the world's population live in countries
 
where 





the number of infants with 
CRS born each year worldwide was
 
estimated to be 110,000 in 1999 [3]. About 5 
to 25% of women of childbearing age lack 
rubella IgG antibodies and are susceptible to 
primary infection [2, 7]. Rubella is 
transmitted by the respiratory route. The 
incubation period is 13 to 20 days, during 
which a viraemia occurs and virus 
disseminates throughout the body [12]. In 
adults a prodromal phase may be present 
with fever and malaise for a day or two 
before the rash develops [13, 14].  The rash 
is typically a maculopapular rash, which first 
appears on the face and then spreads to the 
trunk and the limbs. The rash seldom lasts 
more than 3 days. The exact mechanism of 
how the rash is induced is uncertain but an 
immunopathological mechanism may be 
present [15]. Lymphadenopathy may 
precede the rash by up to a week and 
persists up to 2 weeks after the rash has 
gone [16]. 
Rubella has a worldwide distribution. Before 
the introduction of vaccination outbreaks 
tend to occur in spring and summer [6]. 
Infection is uncommon in preschool children 
but outbreaks involving school children and 
young adults are common (7, 8]. In general, 
about 50% of 10 year olds have rubella 
antibodies. About 80% of women of 
childbearing age were found to be immune 
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in the pre-vaccination era [10] Children 3 
to10 years are most frequently affected. 
Despite the vaccination program 5 to 10 % 
of women of child bearing age are 
susceptible to Rubella infection [11].So far, 
no vaccination programme has been put in 
place in Cameroon. Statistics from the World 
Health Organization (WHO) show that this 
virus is present in Cameroon with confirmed 
cases: 83 in 2004, 159 in 2005, 58 in 2006, 
and 126 in 2007[4, 7]. These cases were 
initially suspected cases of measles which 
turned out negative and rather tested 
positive for rubella. Considering the fact 
Cameroon is one of the countries not 
implementing a vaccination scheme, the 
danger of an eventual outbreak cannot be 
over emphasized. There is the need to know 
the epidemiology of rubella in pregnant 
women because of the congenital rubella 
syndrome (CRS), and the de novo infection 
in the first trimester of pregnancy. The 
purpose of this study was to identify the 
susceptibility of women to the rubella virus in 
Yaoundé through the assessment of the 
Immunoglobulin IgM protective antibody 
level in Pregnant women at the Yaoundé 
Gynecology, Obstetric and Pediatric 
Hospital (HGOPY) in Cameroon Samples 
were collected randomly at (YGOPY) 
Cameroon, so that the data generated from 
the study would be useful for introducing 
vaccination in Cameroon. 
MATERIALS AND METHODS 
Study Design 
A Cross-sectional descriptive study was 
carried out in pregnant, outpatient’s women 
visiting the Yaoundé Gynaeco-Obstetric and 
Pediatric Hospital (YGOPH). This hospital 
was chosen because of its high patient’s 
attendance as well as logistic and 
administrative facilities. 
Collected blood specimens were analyzed at 
the Center for the Study and control of 
Communicable Diseases (CSCCD), of the 
Faculty of Medicine and Biomedical 
Sciences (FMBS), University of Yaoundé. 
This study was for 3 months and ran from 
April to July 2008. 
The Inclusion Criteria, was basically to be a 
pregnant woman, sign the consent form as a 
volunteer, with no cash involvement and the 
acceptance to participate in the study. 
The Exclusion Criteria included the refusal 
to participate in the study  
Sample Size: The minimum acceptable 
sample size was 207 as calculated using 
Lorenz formula for two-tailed dichotomous 
variables. 
Where N = sample size, Za= the normal 
distribution value for which a=0.05 (the 
standard normal deviate=1.96) 95%, 
confidence interval; a=level of statistical 
significance (a=0.05),  p=prevalence (9), 
Q=1-p, D=degree of precision= level of error 
we want to accept (D=0.05 for a 95% 
confidence interval)  
Using Z a= 1.96, P = 84 % (9), D = 0.05, 
N= (1.96)
2 
X (0.84) X (0.16) ~207 




 Sampling Method 
82 
 
Consecutive sampling was used whereby 
subjects who satisfy the inclusion criteria 
during the study period were included in the 
study.  
Data and blood specimen collection 
Each patient was made to sit comfortably, 
then the arm region intended for the 
venupuncture was cleansed with an alcohol 
swab, the selected vein pricked with a sterile 
needle attached to a syringe (10 ml) and 4-5 
ml of blood drawn. The needle was then 
withdrawn under a dry cotton and brief 
haemostasis effected by digital pressure 
with the swab at the puncture site. The 
blood sample was put in a sterile dry tube. 
Centrifugation was done at 2000 rotations 
per minute (rpm) for 5 minutes. Serum was 
collected in cryotubes and stored in 
refrigerator at -20 degree Celsius. Cryotubes 
were put inside a cold box and transported 
to the CSCCD of the FMBS. Laboratory 
analysis was done at the end of the month. 
Laboratory analysis of specimens: 
Reagents and specimens were brought at 
room temperature before use. Testing for 
the presence of rubella virus was done using 
Human-Rubella IgG ELISA (26) this is an 
enzyme immunoassay for the detection of 
rubella antibodies in the plasma or serum. 
10µl of patient serum were diluted to 1ml of 
buffer and mixed properly. Well A1 was left 
blank while B1/C1 100 ml of negative control 
(NC) was put. Dl/E1 100µl of cut off control 
(CC) and F1/G1 100 ml of positive control 
(PC).100µl of each serum to be tested was 
added to the microtitre plate. The microtitre 
plate was the covered with adhesive foil and 
allowed to incubate for 30 minutes at 25 
degree Celsius. They were then washed 4 
times with 350µl washing solution using an 
automatic washing device. Each well was 
filled with 100 µl conjugate solution (Anti-
human IgG rabbit, peroxidase-conjugated). 
Then, the plate was covered, and incubated 
at 25 degree Celsius for 30 minutes, then 
washed 5 times as above. Then, each Well 
was filled with 100µl of substrate reagent (3 
3`, 5, 5` tetramethylbenzidin (TMB hydrogen 
peroxide). The plate was covered and 
incubated for 15 minutes at 25 degree 
Celsius in a dark room. 100 µl of STOP 
solution was added to each well. The Wells 
were read using a zero-balanced 
photometer at 450 nm within 30 minutes 
after termination of the reaction, using a 
reference wavelength of 690nm. 
Calculation of control values and cut-off: 
Mean absorbance values of negative control 
(NC) in wells B1 and C1, mean negative 
control (MNC) in wells D1 and E1,  mean 
cut-off control (MCC), and Positive control 
(PC) in wells F1, and G1 mean positive 
control(MPC) were calculated according to: 
MNC=A450 (B1) +A450(C1) /2; MCC=A450 (D1) 
+A450(E1) /2; MPC=A450 (F1) +A450(G1) /2 
The test was considered valid as the 
following criteria were met: Substrate blank in 
well A1 <0.150;  MNC ≤MCC;  MPC >0.750; MPC: 
MNC >2.5 .   Interpretation of results: A450(patient) 








Due to physiological and analytical 
variations, patient’s results lying at 15% 
above or below the calculated cut-off were 
considered equivocal [26]. 
Quantitative Estimation of rubella IgG in 
patient samples   
 Each plate test was validated when the 
absorbance of the mean cut off control were 
<10 iu/ml and the absorbance of the positive 
control >15 iu/ml and values in-between 
were considered equivocal.   
Data Quality Control: To guarantee the 
authenticity of the information collected, 
A standardized questionnaire was used to 
record the information obtained from every 
patient, to ensure uniformity.The 
questionnaire were pre-tested during a short 
pilot study on few (10) subjects before 
recruitment proper. The questionnaire was 
then revised following the results of this pilot 
study before the main study started. 
The data was filled by the researcher 
personally to ensure precision of 
information. 
Data Presentation and Analysis: The data 
collection forms were first of all cross-
checked to make sure all the relevant 
information was appropriately entered. The 
EPI INFO version 3.3.2, February 09, 2005 
(Centre for the Disease Control and 
Prevention, Atlanta, Georgia, USA) 
statistical software was used for the data 
entry, validation and analysis. To ensure 
accuracy of entry a CHECK programme was 
created. This programme ensured that only 
legal entries and data in specified ranges 
and codes were entered. Discrepant records 
were subsequently reviewed and corrected. 
All entries on computer were further 
checked against that on paper, item by item. 
Finally, frequency tables were generated for 
variables in order to examine for unusual 
entries. Spearman correlations were used to 
calculate the various variables. The 
prevalence of rubella virus among pregnant 
women was calculated as: 
P=N1/N2*100%: Where P is prevalence; N1 
the total number of women presenting 
antibodies to the rubella virus; N2 the total 
number of women tested for antibodies.  
Ethical considerations 
Institutional Ethical Clearance was procured 
from the Faculty of Medicine and Biomedical 
Sciences (FMBS) ethical committee. 
Informed, written and signed consent was 
obtained from subjects by way of a consent 
form, after the purpose and the procedure of 
the study had been explained. Non-
consenting individuals were excluded from 
the study. Records were kept strictly 
confidential with code numbers used at the 
registration of each participant and records 
accessible only to members of the 
immediate research team. The entire 
procedure was of minimal risk to the 
subjects. Each needle was used once and 
properly discarded after use. The informed 
consent of each subject was sought 
systematically before recruitment. The aim 
and the nature of the study were explained 
to each patient and her role in the study 
clarified. Confidentiality was strictly 
respected and all records were accessible 
only to members of the immediate research 
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From April to July 2008, two hundred and 
eleven (211) pregnant women were 
recruited in our study population from the 
Yaoundé Gynecology, Obstetric and 
Pediatric Hospital.  
General Characteristics of the subjects of 
study 
The age of the subjects ranged from 14 to 
46 years. The 21-25 years and 26-30 years 
were the most represented, with 29.4% and 
33.6% respectively, as shown in Table 1, the 
mean age was 27±5.99 years. The subjects 
were distributed in first, second and third 
trimesters as shown in figure 1.   
Table 1:  Distribution of subjects into age groups 
Age Frequency Mean percentage 
<15 1 0.5±0.0 
16-20 15 7.1±1.3 
21-25 62 29.4±6.0 
26-30 71 33.6±5.9 
31-35 36 17.1±3.2 
36-40 18 8.5±2.2 
40+ 8 3.8±0.8 
Total 211 100±7.6 
P-value 0.3922  
 
Fifty-four (54) of the subjects were in the first 
trimester of pregnant. The partition of 
subjects based on history of premature 
delivery showed that (Figure 2) showed that 
a low incidence of subjects 24 
 
 (11.37%), with any history of premature 
delivery. There was a high subject 
population 187 (88.63) with no history of 








Figure 1: Distribution of subjects by pregnancy duration in trimester 
 
The calculated percentage shown is with 
respect to the Sero status. (Figure 3) The 
age group 21 to 25 and 26 to 30 years had 
the highest prevalence of the antibodies  
 
 
against the rubella virus, with a mean age of 
27.0±5.99 years. No statistical difference 







Figure 2: Distribution of subjects according to premature delivery 
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                      Figure 3: Classification of rubella seropositivity/negativity with respect to age group 





























            Fig 4: Mean Antibody titre and age distribution 
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              Figure 6: Correlation between antibody titre and number of abortions  
 
There was a steady increase in the mean 
antibody titre levels with increase in age 
(Figure 4) There is a significant difference 
between mean antibody titre of the women 
age values (P<0.0001).This showed that as 
the age increases, the antibody titre 
significantly increased. Investigation of the 
relationship between age and antibody titres 
by the Spearman Correlation analysis 
values showed that there was a significant 
positive correlation (p<0.01, r=0.549, N= 
211) between the subject ages and the 
antibody titre. This means that as the age 
increases, the antibody titre increases. 
(Figure 5). Investigation to establish any 
relationship between antibodies titre and the 
number of abortions by the Spearman 
correlation showed that there was a positive 
but weak correlation (P<0.01, r=0.246 
N=211) between the number of abortions 
and the antibody titre. (Figure 6). 
 
DISCUSSION 
The investigation conducted on the 
seroprevalence of rubella virus amongst 
pregnant women visiting the Yaoundé 
Gynecological, Obstetric and Pediatric 
Hospital (HGOPY) showed that of the 211 
pregnant women randomly selected visiting 
prenatal consultation. The seroprevalence of 
the rubella virus was found to be 88.6% 
while 9% were seronegative (susceptible) to 
the rubella virus. 5 women (2.4%) were 
found to be equivocal. The latter may be due 
to re-infection cases, the IgG is highly 
elevated whilst IgM may be demonstrable, 
giving equivocal results [8]. For such cases, 
it is recommended to collect fresh samples 
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assay in parallel [25], to confirm these 
equivocal cases. However, it was not 
possible to repeat the tests for these 
samples due to the time allocated for this 
study and also difficulties involved in 
scheduling another meeting with the 
subjects.  
The seroprevalence of (88.6 %)  recorded in 
this study is similar to those reported in 
other African countries in pregnant women, 
women of childbearing age, women and 
men [40, 41, 42,43, 44, 46, 47, 48, 48, 49, 
38, 51, 52].The assays for rubella-specific 
IgG varied between studies, as did the titre 
that was considered positive. The 
Haemagglutination Inhibition (HI) test, which 
is considered the reference stardard was 
used in most of these studies, but some 
used Single Radial haemolysis (SRH), latex 
Agglutination, or Enzyme-based 
Immunoassay (EIA). Although there is a 
general agreement between these tests, the 
results vary between laboratories, and those 
of different assays or different commercial 
kits may not be strictly comparable [2, 10, 
17]. 
None of these women had previous history 
of vaccination of rubella virus. This high 
prevalence might suggest the presence of 
the wild type virus [ 12, 13, 22, 25] also, 
since it is a hospital based study, and most 
of the women were living in urban areas, the 
seroprevalence might be higher than normal 
due to overcrowding and the ease with 
which the virus spreads amongst 
unvaccinated population [16-21, 36). It might 
also be as a result of selection bias due to 
exclusion of women who did not come for 
prenatal checks. Previous studies performed 
in different populations and study zone 
reported seroprevalences ranging from 59% 
to 94% [22, 25, 26, 40, 41, 42]. 
Seroprevalence of up to 90% in countries 
without any mass vaccination program, are 
generally a reflection of post-epidemic 
immunity (37). We cannot conclude that 
these cases were from post epidemic 
immunity since no data is available for 
epidemics in Cameroon Rubella natural 
infection is followed by a high level of 
protection from re-infection [19] However, 
re-infection can occur which is generally 
asymptomatic and in pregnancy it poses 
minimal risk to the fetus [18]. Studies to 
investigate any relationship between 
maternal age and the mean antibody titre 
(IU/ml) within the subjects ranging from 14 
to 46 years showed that the 21 to 25 years 
and 20 to 30 years band were the most 
represented with  mean values of 29.4% and 
33.6% respectively. An observation of a 
steady increase in the antibody titres levels 
and the mean ages was recorded. This 
increase, was significant (p<0.0001). Also a 
significant spearman moment product 
correlation (P<0.01, r=0.549,N=211) was 
observed between the age and antibody titre 
levels (iu/ml).This suggests that as the age 
increases, the antibody titre significantly 
increases as confirmed by other publications 
[37, 39]. 
 
The majority of pregnant women were in 
their third trimester of pregnancy (39.3%) 
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the mean antibody titre was higher in the 
first trimester no statistical significant 
difference was observed between the first, 
second and third trimesters and mean 
antibody titre (P=0.0926) and also no 
Spearman correlation between antibody titre 
and pregnancy duration in trimesters 
(p=0.07). This may imply the rubella virus 
does not affect pregnancy duration. This 
correlates with previous datum that shows 
that there was no relationship between 
pregnancy duration prevalence of rubella 
[38]. 59.7% of the subjects did not have any 
history of abortion and 40.3% had previous 
history of abortion. The higher the antibody 
titre, the greater the chances of abortion 
occurring [16, 26]. A look into the variation of 
number of abortion with antibody titre was 
necessary. Looking at the relationship 
between number of abortions and the 
prevalence of rubella, we observed that the 
prevalence of rubella significantly increased 
with the number of abortions (P<0.05) 
furthermore, there was a significant but 
weak Spearman correlation (P<0.01, 
r=0.246 N=2.) between the number of 
abortions and the Antibody titre.  This 
means that the higher the antibody titre, the 
higher the probability of abortion, implying 
that those with higher rate of abortions had 
higher antibody titre. Rubella virus enters 
the fetus during the maternal viraemic phase 
through the placenta [3, 21, 29] The damage 
to the fetus seems to involve all germ layers 
and results from rapid death of some cells 
and persistent viral infection in others [22, 
48, 49]. However, since the study was cross 
sectional, it is difficult to say whether the 
occurrence of high antibody titre preceded 
or followed the abortions recorded. 
Generally, the rubella virus plays a 
significant role in the occurrence of abortion 
in the study population. [2, 7, 53]. There was 
no correlation between the antibody titre and 
the occurrence of premature births 
(P=0.947, r=0.012, N=24). This either 
suggests that there were no enough rubella 
antigens to induce active immunity against 
the virus and since it was a cross sectional 
study, no information was present to say if 
the occurrence of premature birth was due 
to high antibody titres. Thus these 
premature cases might have either resulted 
from low titre of antibody with encountered 
with the virus or from other sources.  
Rubella virus enters the fetus during the 
maternal viraemic phase through the 
placenta [21]. The damage to the fetus 
seems to involve all germ layers and results 
from rapid death of some cells and 
persistent viral infection in others [22]. 
Chromosomal aberrations and reduced cell 
division are present. The fetus is almost 
invariably infected if the mother is infected 
during the first trimester. After the first 
trimester, the virus is isolated infrequently 
from the neonates, probably because fetal 
immune mechanisms can be activated and 
infection can be terminated. [23, 45].  
Rubella virus is seldom isolated from infants 
whose mothers acquired rubella after the 
first trimester. However rubella- specific IgM 
can be detected in a high proportion of these 
infants which means that they were infected. 
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Major abnormalities are very rare because 
organogenesis is complete by 12 weeks and 
the immune response may be more 
developed [29]. Deafness and retinopathy 
(which does not affect vision), are likely to 
be the only abnormalities associated with 
post first trimester rubella. Deafness is 
usually the sole clinical manifestation of fetal 
infection occurring between 13 and 16 
weeks [30]. 
Rubella virus specific IgM antibodies are 
present in people recently infected by 
Rubella virus but these antibodies can 
persist for over a year and a positive test 
result needs to be interpreted with caution 
[6].The presence of these antibodies along 
with, or a short time after, the characteristic 
rash confirms the diagnosis [2, 11, 35]. 
Serology is the mainstay of diagnosis of 
rubella infection. A recent rubella infection 
can be diagnosed by [26] detection of 
rubella-specific IgM, [8] rising titres of 
antibody in HAI and ELISA tests, and 
seroconversion [27]. It is essential to obtain 
accurate information relating to the date and 
time of exposure, the date of onset of 
illness, a history of previous rubella 
vaccination, as well as previous results of 
rubella screening tests. Blood should be 
collected from pregnant women with 
features of rubella-like illness as soon as 
possible after onset of symptoms. [26]. A 
significant rise in HAI antibodies can often 
be demonstrated. However, rubella-specific 
IgM is the test of choice for demonstrating 
current infection. It has been shown though 
that low and transient level of IgM can be 
detected in cases of reinfection [26, 31, 50]. 
Furthermore, low levels of rubella IgM may 
persist for a few months to 4 years following 
rubella vaccination.  
Typical serological events following acute 
rubella infection [8], note that in reinfection, 
rubella-specific IgM is usually absent or 
present at a low level transiently ELISA is 
now the test of reference in many 
laboratories but it is considerably more 
expensive than the SRH. An antibody titre of 
equal or greater than 15 IU/ml is regarded 
as being immune to rubella. However, there 
is some controversy as to the 15 IU/ml cutoff 
since it was arrived at empirically in the first 
place. It is quite clear that lower levels of 
antibody, such as 10 IU/ml would probably 
be protective as well. HAI is not used for 
rubella antibody screening because it is not 
sensitive enough [18]. 
It is important that women are vaccinated 
prior to their first pregnancy [12]. United 
States recommendations are for childhood 
vaccination to prevent epidemics, combined 
with vaccination of susceptible, non-
pregnant adolescent and adult females [37]. 
The vaccine is contraindicated for pregnant 
women, but when unwittingly used, no 
problems have been seen. If the patient is 
pregnant and seronegative, the pregnancy 
should be monitored carefully and the 
patient vaccinated postpartum [1, 5, 8]. This 
study certainly has certain limitations since it 
is a hospital based study selection bias 
could have occurred due to the criteria of 
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selection since some women might not have 
visited prenatal consultation. The study is 
limited to females visiting the prenatal 
consultation and it is difficult to extrapolate 
the results to the general population. There 
are constraints on the use of data from a 
cross-sectional survey to estimate the 
transmission dynamics of rubella. The 
duration of study was too short to give a 
strong conclusive finding. However, this 
preliminary investigation has provided a 
platform form a wider and long duration 
project as a follow up by a team of PhD 
students. 
CONCLUSION:  
The majority of pregnant women attending 
the Gynecology Hospital possess a 
protective level of Rubella IgG antibodies. 
However, 9% are susceptible to rubella. 
Furthermore, rubella antibodies increase 
with increasing number of previous 
abortions and with maternal age. Some 
recommendations to be made is geared 
towards encouraging the ministry of Public 
Health in Cameroon the necessity for a  
 
mass vaccination program, Increase 
awareness through media. There is also the 
need for the clinician to systematically check 
rubella serology in all female desiring 
pregnancy and in women of child bearing 
age, and also prenatal screening of 
pregnant women and vaccination of those 
who are seronegative to reduce the 
morbidity and mortality related to rubella 
virus in new born babies. 
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